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Pospiech* 
Department of Biology 
Lake Forest College 
Lake Forest, Illinois 60045 
 
Summary 
 
The aging process can be accelerated by numerous 
cellular and molecular variables.  Progeroid 
syndromes are one such example. The phenotypes 
of Hutchinson-Gilford Progeria Syndrome (HGPS) 
and Restrictive Dermopathy (RD) are both caused 
by an irregular pathway of the processing of 
prelamin A to mature lamin A, an integral 
component of the nuclear lamina. In wild-type cells, 
prelamin A undergoes farnesylation followed by 
cleavage that is carried out by the enzyme 
Zmpste24. A 50 amino acid deletion in the LMNA 
gene found in HGPS patients eliminates the 
cleavage site in prelamin A, causing an 
accumulation of farnesylated prelamin A. The 
buildup of this protein, known as progerin/LA50, 
occurs at the nuclear rim. In RD, nonfarnesylated 
and farnesylated prelamin A build up due to a 
deficiency in the Zmpste24 cleaving enzyme. In 
both syndromes, however, the accumulation of the 
different forms of prelamin A causes nuclear shape 
abnormalities and leads to phenotypes resembling 
premature aging. Currently, there are no known 
cures for HGPS and RD. However, FTIs and gene 
therapy are being studied as possible treatments. 
With continued research, more can be learned 
about the normal aging process, which could be 
applied in understanding progeroid syndromes and 
developing alternative treatments. 
 
Introduction 
 
Aging is a normal physiological process that can be 
altered by various cellular and molecular factors. 
Progeroid syndromes include multiple diseases in 
which premature aging occurs. Hutchinson-Gilford 
progeria syndrome (HGPS) and Restrictive Dermopathy 
(RD) are two such examples (The Progeria Research 
Foundation, 2006).  
Since the late nineteenth century when 
HGPS was first described, approximately 100 known 
cases have been reported worldwide (Ackerman, 2002; 
Hennekam, 2006; Monu et al., 1990; The Progeria 
Research Foundation, 2006). It is estimated that HGPS 
affects 1 in 4 million children, while the actual 
estimation is 1 in 8 million (Ackerman, 2002; 
Hennekam, 2006; Monu et al.., 1990).  
Children with autosomal dominant HGPS appear 
normal at birth and are usually diagnosed around two 
years of age (Hennekam, 2006; Wisuthsarewong, 
1999). Diagnostic characteristics include cessation of 
growth and excessive weight reduction due to loss of 
subcutaneous fat, as well as a noticeable degeneration 
of skin, muscle, and bone. On average, this 
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degenerative disease results in death during early 
adolescence due to heart failure (Wisuthsarewong, 
1999; Hennekam, 2006).  
HGPS phenotypes are a consequence of 
misshapen nuclei that interrupt a number of vital cell 
processes. In 2003, it was discovered that a missense 
mutation in the LMNA gene causes a 50 amino acid 
deletion in the transcribed protein prelamin A 
(Goldman, et al., 2004). This mutant prelamin A is 
unrecognizable by Zmpste24, the enzyme involved in 
the final processing step of prelamin A to mature lamin 
A (Goldman, et al., 2004). This leads to the buildup of 
farnesylated prelamin A on the nuclear membrane and 
has deleterious effects on the cell (Goldman, et al., 
2004).  
In Restrictive Dermopathy (RD), a more 
severe and rare form of progeria, a similar alteration in 
the processing of prelamin A occurs, leading to 
abnormally shaped cell nuclei (Navarro et al., 2005). In 
HGPS, a mutation affects the protein prelamin A 
directly, whereas in RD, a mutation deletes Zmpste24, 
which is necessary for processing mature lamin A 
(Navarro et al., 2005). This neonatal skin disease is 
fatal because rupture of the placental membrane results 
in a premature birth during approximately the thirty-
fourth week of pregnancy (Navarro et al., 2005; 
Wesche et al., 2001). However, if infants live to term, 
they often die within several days of birth. As of 2001, 
there had been 35 reported cases worldwide (Wesche 
et al., 2001).  
Overall, symptoms of RD are similar to that of 
HGPS, but more severe. Symptoms characteristic of 
RD include impaired motor and voluntary movement, 
abnormal joint function, low-set malformed ears, a small 
lower jaw and pinched nose, widely spaced eyes, and a 
fixed open mouth in a characteristic “o” shape (Moulson 
et al., 2005; Navarro et al., 2005; Wesche et al., 2001). 
Given the infrequency of progeroid diseases 
worldwide, little attention has been paid to these 
premature aging syndromes. However, due to the 
recent discovery of their molecular mutations and 
pathologies, HGPS and RD have received greater 
attention in the past few years. Having identified the 
steps associated in the production of mature lamin A, 
as well as its role within a cell in relation to the normal 
process of aging, research is focused on potential 
treatments for both phenotypic and genotypic effects of 
these diseases (Eriksson et al., 2003). Presently, 
therapies for progeroid syndromes simply treat their 
associated symptoms; however, promising treatments 
include gene therapy and modification of lamin A 
processing through the use of pharmaceuticals (Fong et 
al., 2006; Scaffidi & Mistelli, 2005). Therapeutic 
intervention of these progeroid syndromes is at the 
forefront of current biological studies, which will 
hopefully yield results within the next few years.  
 
The Genetic Basis of Normal Aging 
 
Before 2003, the molecular foundations of HGPS and 
RD were unknown (Badame, 1989; The Progeria 
Research Foundation, 2006). However, prior 
speculation focused on the possibility that a mutation in 
common aging genes, such as klotho, Methuselah, and 
sgs1, could potentially lead to genetic instability and 
accelerated aging.  
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  Klotho is one of several genes that affects the 
normal aging process when not expressed. The 
transcribed klotho protein is a hormone targeted 
primarily by the kidneys and cardiovascular organs, 
where it reduces insulin receptor substrate (IRS) protein 
activity, as well as insulin and IGF1 signaling (Kurosu et 
al., 2005). These processes have evolved due to their 
suppressive aging qualities (Kurosu et al., 2005). 
Kurosu et al. (2005) observed that all mouse models 
expressing the klotho hormone exhibited normal aging. 
However, in mice where the klotho gene was not 
expressed, symptoms associated with aging were 
observed, especially degeneration in aforementioned 
target organs (Takahashi, 2000). Aging symptoms 
related to the absence of klotho include atherosclerosis, 
osteoporosis, emphysema, and infertility (Arking et al.., 
2002). When the klotho protein was reintroduced into 
these knockout mice, the aging phenotypes observed 
were significantly decreased, suggesting that klotho 
plays a critical role in controlling aging and organ 
degeneration (Takahashi, 2000).  
Another anti-aging gene, Methuselah, is 
involved in stress response pathways and is associated 
with regulating longevity (Lin et al.., 1998). Lin et al. 
(1998) demonstrated that excessive expression of the 
Methuselah gene in fruit flies increased life-span by 
about 35% compared to wild-type flies (Lin et al.., 
1998). These findings suggest that the Methuselah 
gene is critical for a cell’s survival due to its ability to 
maintain homeostasis.  
The sgs1 gene, a member of the helicase 
family, is involved in maintaining genomic stability, 
chromosome segregation during mitosis, and DNA 
replication (Sinclair et al.., 1997). Given its role in cell 
division and genetic organization, the absence of sgs1 
contributes to accelerated aging (Sinclair et al., 1997). 
Sinclair et al. (1997) used a yeast model to compare 
normal aging in wild-type cells to accelerated aging in 
sgs1-deficient yeast. Yeast deficient in sgs1 had a 60% 
shorter life span than the wild-type yeast. Additionally, 
premature sterility was observed when sgs1 was 
absent (Sinclair et al.., 1997). Cell division is reduced 
when sgs1 is not expressed, slowly leading to tissue 
and organ deterioration and contributing to the aging 
process. 
The genetic and phenotypic effects of 
abnormal functioning of klotho, Methuselah, and sgs1 
are comparable to the premature aging seen in HGPS 
and RD. Further investigation of aging genes could lead 
to a better understanding of the aging process. 
 
Cause for Premature Aging: Altered Nuclei 
 
Although discoveries about the abovementioned genes 
provided insight into aging, they did not account for 
HGPS and RD. It was thus necessary to use an 
alternative approach to identify the molecular basis of 
these premature aging diseases.  Given that HGPS and 
RD cells are characterized by misshapen nuclei, 
researchers turned to the structural aspects of the 
nucleus for answers (Eriksson et al, 2003). 
 
Nuclear Lamins 
Lamins are a class of intermediate filament proteins 
that polymerize in order to form the nuclear lamina, a 
two-dimensional mesh structure located on the surface 
of the inner nuclear membrane, as seen in Figure 1 
(Alberts et al., 2004).  The primary purpose of the 
nuclear lamina is to provide mechanical support for the 
nucleus, maintaining its shape and structural integrity 
(Cao et al., 2007).  The lamins are also found 
throughout the nucleoplasm and are involved in a 
variety of functions, including DNA replication, 
transcription, chromatin organization, and apoptosis 
(Figure 1) (Goldman et al., 2004). Lamins are also 
significant in the process of assembling and 
disassembling the nucleus during cell division (Alberts 
et al., 2004).   
 Lamins are divided into two sub-categories, 
A-type lamins and B-type lamins, which differ according 
to their primary sequence, pattern of expression, and 
biochemical properties (Goldman et al., 2004). The 
LMNA gene encodes the A-type lamins: lamin A, lamin 
C, lamin C2, and lamin A10 (Cao et al., 2007).  The 
gene contains twelve exons and encompasses 
approximately 25 kilobases of genomic DNA (Eriksson 
et al., 2003).  Mutations in the LMNA gene have been 
implicated as the cause of a number of genetic 
disorders that are collectively classified as 
laminopathies (Eriksson et al., 2003). 
 
Lamin A Synthesis: A Multi-Step Process 
Lamin A synthesis occurs at the periphery of the 
nuclear envelope and includes a number of processing 
steps that change the precursor protein, prelamin A, 
into mature lamin A (Figure 2a).  After translation of 
prelamin A from the LMNA gene, the CAAX motif at the 
carboxyl terminus undergoes farnesylation followed by 
the proteolytic cleavage of the AAX 
sequence and carboxymethylation (Goldman et al., 
2004). Finally, the last fifteen amino acids on the C-
terminus of prelamin A are cleaved by the 
endoprotease Zmpste24, producing the mature, 
unfarnesylated lamin A (Sinesky et al., 1994). 
Mutations in lamin A have been observed, to 
a lesser degree, in the cells of healthy individuals as 
they age (Scaffidi & Misteli, 2006). This suggests that 
lamin A plays a role in normal physiological aging, thus 
implying that mutations disrupting lamin function could 
additionally play a role in accelerated aging diseases. 
 
Hutchinson-Gilford Progeria Syndrome 
 
Having identified the role of nuclear lamina in 
maintaining nuclear integrity and cellular processes, the 
link between misshapen nuclei seen in HGPS became 
clear in 2003 when a mutation in the LMNA gene was 
implicated as the cause of HGPS (Eriksson et al., 2003; 
The Progeria Research Foundation, 2006). A mutation 
found in the LMNA gene in HGPS patients leads to an 
alteration in the transcribed lamin A protein, resulting in 
the classification of HGPS as a laminopathy.  Studies 
have shown that the mutated lamin A protein is 
responsible for alterations in the shape and structure of 
HGPS cell nuclei, as well as in disrupting the normal 
cell cycle and mitosis.  Furthermore, these cellular 
abnormalities are thought to contribute to the 
characteristic phenotypes associated with HGPS.   
 
Lamin A Synthesis: A Multi-Step Process 
Lamin A synthesis occurs at the periphery of the 
nuclear envelope and includes a number of processing 
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steps that change the precursor protein, prelamin A, 
into mature lamin A (Figure 2a).  After translation of 
prelamin A from the LMNA gene, the CAAX motif at the 
carboxyl terminus undergoes farnesylation followed by 
the proteolytic cleavage of the AAX sequence and 
carboxymethylation (Goldman et al., 2004). Finally, the 
last fifteen amino acids on the C-terminus of prelamin A 
are cleaved by the endoprotease Zmpste24, producing 
the mature, unfarnesylated lamin A (Sinesky et al., 
1994). 
Mutations in lamin A have been observed, to 
a lesser degree, in the cells of healthy individuals as 
they age (Scaffidi & Misteli, 2006). This suggests that 
lamin A plays a role in normal physiological aging, thus 
implying that mutations disrupting lamin function could 
additionally play a role in accelerated aging diseases. 
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Figure 2. Pathways of Prelamin to Lamin A.  
 A: In a wild-type cell, farnesylation of a lipid anchor occurs, followed by cleavage and methylation at the C-terminus. The Zmpste24 enzyme 
then cleaves to form mature Lamin A.  
 B: The lack of Zmpste24 found in RD prevents the final cleavage needed to form mature lamin A.  
 C: The deletion in HGPS eliminates the cleavage site, resulting in a buildup of farnesylated prelamin A (progerin).  
Figure 1. The Importance of the Nuclear Lamina. The nuclear lamina are intermediate filaments that create a meshwork of head to tail 
polymers lining the nucleoplasmic surface of inner nuclear membrane. Nuclear lamina provide structural support for the nucleus, allowing it 
to maintain its shape. Additionally, lamina aid in organizing nuclear processes such as, DNA replication, RNA transcription, interphase 
heterochromatin anchoring, mitosis, cell cycle regulation, and apoptosis. In the absence of nuclear lamina, not only is the integrity of the cell 
compromised, but many cellular processes are disrupted. 
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Hutchinson-Gilford Progeria Syndrome 
 
Having identified the role of nuclear lamina in 
maintaining nuclear integrity and cellular processes, the 
link between misshapen nuclei seen in HGPS became 
clear in 2003 when a mutation in the LMNA gene was 
implicated as the cause of HGPS (Eriksson et al., 2003; 
The Progeria Research Foundation, 2006). A mutation 
found in the LMNA gene in HGPS patients leads to an 
alteration in the transcribed lamin A protein, resulting in 
the classification of HGPS as a laminopathy.  Studies 
have shown that the mutated lamin A protein is 
responsible for alterations in the shape and structure of 
HGPS cell nuclei, as well as in disrupting the normal 
cell cycle and mitosis.  Furthermore, these cellular 
abnormalities are thought to contribute to the 
characteristic phenotypes associated with HGPS.   
  
Mutations in the LMNA Gene 
Most cases of HGPS are associated with a de novo, or 
newly generated and not inherited, point mutation in 
exon 11 of the LMNA gene (Eriksson et al., 2003).  This 
mutation involves a single-base substitution at position 
1824 (GGC > GGT) but does not cause an amino acid 
change (Eriksson et al., 2003).  Rather, the mutation 
results in the activation of a cryptic splice site, 
producing a mRNA molecule that lacks 150 nucleotides 
within exon 11.  The resulting prelamin A molecule 
contains an internal deletion of 50 amino acids near the 
C terminus (Eriksson et al., 2003).  This prelamin A 
undergoes farnesylation, but lacks the site for 
endoproteolytic cleavage by Zmpste24 and thus retains 
its farnesylated CAAX box motif. It is therefore 
incapable of forming mature lamin A (Figure 2c) 
(Eriksson et al., 2003).  Furthermore, the deletion 
includes the elimination of at least one phosphorylation 
site for lamin A (Eriksson et al., 2003). The abnormal 
lamin A protein that is produced is referred to as 
progerin or LA50. Production of lamin C is unaffected 
by the LMNA mutation.  
 
Changes in Nuclear Architecture 
The accumulation of progerin/LA50 within cell nuclei 
can be associated with substantial changes in nuclear 
architecture.  The protein progerin/LA50 is targeted to 
the nuclear rim, where it disrupts the integrity of the 
nuclear lamina, producing severely misshapen nuclei 
(Eriksson et al, 2003). Moreover, when bacterially 
expressed progerin/LA50 was injected into healthy 
fibroblast cells, many of the cell nuclei resembled 
HGPS cells, indicating that the mutant protein has a 
direct and immediate effect on nuclear shape (Goldman 
et al., 2004).   
The architectural irregularities observed in 
HGPS cells include lobulation or blebbing of the nuclear 
envelope, as well as thickening of the nuclear lamina, 
loss of peripheral heterochromatin, and clustering of 
nuclear pores. Moreover, the expression of 
progerin/LA50 leads to genome instability, DNA repair 
defects, and changes in histone methylation (Goldman 
et al., 2004; Dechat et al., 2007).  The structural defects 
observed in cell nuclei worsen as the cells age, 
indicating that the increasing concentration of the 
mutant protein amplifies its deleterious effects on the 
cell (Goldman et al., 2004).   
 
Cell Cycle Abnormalities 
The presence of progerin/LA50 has also been 
associated with disruptions in the progression of the cell 
cycle, including mitotic defects. During mitosis, 
progerin/LA50 mislocalizes into insoluble cytoplasmic 
aggregates and membranes, causing abnormal 
chromosome segregation and binucleation (Cao et al., 
2007). Furthermore, progerin/LA50 interferes with the 
targeting of the components in the nuclear lamina into 
daughter cells during early G1, delaying the onset and 
progression of cytokinesis (Dechat et al., 2007). This 
aggregation has also been associated with 
abnormalities in the retinoblastoma protein (Rb)-
mediated transition from G1 to S phase as a result of 
the inhibition of cdk4 activity (Dechat et al., 2007). 
Interestingly, studies have indicated that the 
abnormalities observed in nuclear architecture and in 
various stages of the cell cycle that are attributable to 
the expression of progerin/LA50 in HGPS may also 
contribute to normal human aging (Cao et al., 2007; 
Dechat et al., 2007; Scaffidi & Misteli, 2006).  
 
Restrictive Dermopathy 
 
Following the identification of the genetic mutation 
causing HGPS, researchers began to investigate the 
cellular and molecular basis of a similar but more 
severe premature aging syndrome, Restrictive 
Dermopathy (RD).  Subsequent studies have found 
mutations in the LMNA gene itself, as well as mutations 
in the gene for the Zmpste24 enzyme within the 
genomes of RD patients (Navarro et al., 2004).  These 
mutations have been associated with an interruption of 
the processing pathway of prelamin A to lamin A in 
addition to the accumulation of truncated prelamin A in 
cell nuclei.  Hence, RD has been classified as one of 
the most terminal laminopathies identified in humans to 
date (Navarro et al, 2004). 
 
Genetic Mutations in RD 
Studies have only isolated two types of genetic 
mutations thus far that can be associated with RD, 
including splicing mutations in the LMNA gene and an 
insertion within the ZMPSTE24 gene, also known as 
FACE-1 in humans (Navarro et al., 2004).  The less 
common mutation, which affects the LMNA gene, is 
similar to that seen in individuals with HGPS.  It 
involves the complete or partial deletion of exon 11 of 
the LMNA gene, which results in the production of 
truncated prelamin A that can not be modified to form 
mature lamin A (Navarro et al., 2004).  It is likely that 
the mutations within the LMNA gene are coupled with 
one or more additional mutations, which would account 
for the greater severity of disease phenotypes in these 
individuals in comparison to HGPS patients with similar 
LMNA mutations (Narvarro et al., 2004). 
In the majority of the individuals studied by 
Navarro et al. (2004), however, there was a mutation 
within the ZMPSTE24 gene, which codes for the 
endoprotease Zmpste24.  This enzyme is known to be 
essential to the normal processing of prelamin A to 
mature lamin A.  Furthermore, ZMPSTE24 mutations 
were identified in all individuals with RD that 
participated in a study by Navarro et al. (2005).  Most of 
these individuals had a thymine insertion within exon 9 
of the ZMPSTE24 gene, leading to the creation of a 
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premature termination codon within the gene (Navarro 
et al., 2005).   Consequently, these individuals lacked 
both the Zmpste24 enzyme and mature lamin A. 
(Navarro et al., 2005).  This suggests that either 
Zmpste24 was not being expressed or was degraded 
within the cell after translation and thus could not 
function in the processing pathway of prelamin A to 
mature lamin A (Navarro et al., 2005). 
Notably, research has suggested that the 
single, heterozygous mutation in the ZMPSTE24 gene 
alone can not be responsible for the RD phenotype, 
namely, the complete loss of Zmpste24 (Navarro et al., 
2005).  This conclusion was reached based on 
evidence that only a complete loss of the Zmpste24 
protein can cause RD (Navarro et al., 2005).  This 
deficit would only be possible, however, with 
homozygous mutations or multiple heterozygous 
mutations within the ZMPSTE24 gene (Navarro et al., 
2005).  This is consistent with the identification of 
several individuals homozygous for the ZMPSTE24 
mutation in exon 9, as well as the identification of 
additional mutations in the ZMPSTE24 gene in the 
remaining RD patients (Navarro et al., 2005). Similar to 
HGPS, the accumulation of farnesylated prelamin A 
causes abnormalities in cellular architecture. 
 
Treating the Lamin A Mutations 
 
Presently, there are no known cures for progeroid 
syndromes. However, clinical studies are currently 
being implemented to investigate possible treatments 
for both the phenotypic and genotypic effects. One 
potential treatment involves targeting the formation and 
amount of prelamin A synthesized by silencing the 
LMNA gene or by artificially correcting the point 
mutation through gene therapy (Fong et al., 2006). 
Another pathway involves altering the prelamin A 
processing steps in order to inhibit the farnesylation of 
prelamin A. 
 
FTI Treatment 
Perhaps one of the most promising treatments for 
HGPS and RD are farnesyl-transferase inhibitors 
(FTIs). FTIs were initially considered for treating cancer 
patients because they were observed to correct 
abnormal CAAX processing in Ras proteins, leading to 
a decrease in tumor genesis (Gelb et al., 2006). Given 
the similar CAAX modification and processing between 
Ras proteins and prelamin A, it seems plausible that 
FTIs could be used to treat HGPS and RD as well (Gelb 
et al., 2006). 
 FTI treatment prevents farnesylation of 
prelamin A, the first step in lamin A processing. Having 
never acquired the farnesyl lipid anchor, mutant 
prelamin A is not targeted to the nuclear membrane but 
rather remains in the nucleoplasm (Gelb et al., 2006).  
 Currently, it has been supported that the 
short term effects of FTI treatment improve cell 
morphology. With the FTI treatment of fibroblast cells 
expressing the missense mutation associated with 
HGPS, there was an overall visual improvement of 
nuclear integrity along with a decrease in nuclear 
blebbing (Toth et al., 2005). Improvements in nuclear 
integrity were seen in correlation with a reduction in the 
buildup of progerin/LA50 on the nuclear rim of FTI-
treated HGPS cells (Toth et al., 2005). Additionally, 
nuclear shape abnormalities and the disrupted 
heterochromatin organization observed in HGPS cells 
can be recovered by treatment with a chromatin-
modifying drug along with FTI treatment (Columbaro et 
al., 2005). In reorganizing nuclear components, as well 
as lowering progerin/LA50 levels, improvement of 
nuclear morphology is dually accelerated. 
 Given the reduction of abnormal cell nuclei, 
the disease phenotypes common in HGPS also 
diminished with FTI treatment (Yang et al., 2006). 
Specifically, a decrease in weight loss, bone 
abnormalities, and loss of adipose tissue were 
observed in mice with a HGPS-like mutation (Yang et 
al., 2006). Reversing such phenotypes would ultimately 
result in a longer life span and greater survival rate, 
thus providing support for the use of FTIs as a potential 
therapy for HGPS.  
Toth et al. (2005) treated fibroblasts from 
human RD patients with FTIs, and found that prelamin 
A was concentrated in the nucleoplasm, while untreated 
cells showed massive accumulation around the nuclear 
rim. FTI treatment of fibroblasts also reduced the 
percent of cells with misshapen nuclei. To further 
explore of the effects of FTIs on RD, Toth et al. (2005) 
examined Zmpste24-deficient cells using Zmpste24
-/-
 
mouse embryonic fibroblasts (MEFs) that had the 
Zmpste24 gene knocked out. Similar results found that 
two different FTIs clearly reduced the amount of 
prelamin A in the Zmpste24
-/- 
MEFs.  
Currently, there is adequate support for the 
treatment of HGPS and RD with FTIs. However, it is 
essential to obtain results from studies looking at the 
long-term effects of FTI treatment and to begin clinical 
trials in order to determine whether FTIs are safe and 
effective for use in humans as well. 
 
Gene Therapy 
 Gene therapy is currently under investigation as an 
alternative treatment for HGPS and RD. One approach 
to this therapy involves inhibiting the expression of 
prelamin A. In 2006, Fong et al. revealed that lamin A 
appeared to be dispensable in mice cells, because the 
lamin C-only (Lmna
LCO/LCO
) mice they created were 
completely healthy, lacking the expected targeting 
problems for lamin C and other proteins such as 
emerin. Only a minimal alteration in nuclear shape was 
present in the cell; this problem was not seen, however, 
in Lmna
LCO/-
 cells. Fong et al. (2006) also found that 
lamin A is not required for the targeting of either lamin 
C or emerin to the nuclear envelope in mouse 
fibroblasts as previously thought. This suggests that 
lamin A and prelamin A are in fact dispensable to the 
cell; however, this does not mean these proteins are 
without purpose.  
With this information, Fong et al. (2006) then 
used gene therapy as a treatment for Zmpste24
-/-
 mice. 
They found that even a single Lmna
LCO
 allele eliminated 
the disease phenotypes normally seen in these 
knockout mice, including osteolytic lesions in bones, 
alopecia, and reduced subcutaneous fat. The scientists 
suggest that the physiological function of prelamin A, 
which is currently unknown, could be relatively 
unimportant from the perspective of a progeria patient. 
Additionally, Scaffidi and Mistelli (2005) suggest that 
simply correcting the appearance of a cryptic splice site 
on the mRNA coding region for the prelamin A protein 
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by using a morpholino oligonucleotide would reverse 
detrimental cell morphology. In doing so, this artificial 
sequence overrides the original DNA sequence 
containing the point mutation, thus allowing for the 
translation of the complete sequence for the prelamin A 
protein (Scaffidi & Mistelli, 2005). The use of this 
morphino oligonucleotide sequence did not affect the 
amount of wild-type lamin A produced in protein 
synthesis; however, levels of progerin/LA50 were 
completely diminished (Scaffidi & Mistelli, 2005). In 
relation to the decrease of progerin/LA50, the nuclei of 
HGPS cells were observed to have less nuclear 
blebbing, suggesting that correction of the alternative 
splice site restores the cell to its normal morphology 
and potentially would correct the diseased phenotypes 
observed in HGPS patients (Scaffidi & Mistelli, 2005). 
 
Conclusion 
 
Hutchinson-Gilford Progeria Syndrome and Restrictive 
Dermopathy are caused by a disruption in the pathway 
in which lamin A is formed from prelamin A.  The cause 
of HGPS was unknown until 2003 when Eriksson et al. 
identified a mutation in the LMNA gene.  The resulting 
50 amino acid deletion prevents the formation of mature 
lamin A.   
Furthermore, in 2004, Navarro et al. 
discovered a common mutation in exon 9 of the 
Zmpste24 gene in RD patients. Consequently, the 
normal Zmpste24 enzyme is not produced and cannot 
function to create mature lamin A. Although the 
Zmpste24 mutation is a major component of RD, it must 
either be a homozygous mutation or be paired with 
another mutation within the ZMPSTE24 gene. 
Scientists have yet to discover the additional mutations 
that contribute to this disease.  
In both HGPS and RD, studies have shown 
that the aforementioned mutations cause changes in 
cellular architecture and disruption of the cell cycle.  
This results in phenotypes of premature aging and early 
death.  
Current treatments used in clinical trials 
include gene therapy and the use of farnesyl-
transferase inhibitors (FTIs). Despite the improvements 
seen in phenotypic expression, it would be pertinent for 
future studies to examine whether FTI treatment has a 
similar effect on HGPS patients that already suffer from 
advanced symptoms (Yang et al., 2006). One main 
drawback in FTI treatment, however, is the inability to 
target prelamin A farnesylation specifically. There are a 
number of proteins involved in essential cellular 
processes that undergo CAAX modification similar to 
that of prelamin A, and thus could be affected as well. 
Further studies regarding the possible toxicity of 
prelamin A and its cumulative effects on the cell are 
also necessary.  
With continued research, more knowledge 
can be gained about the normal aging process. This, in 
turn, could be applied to understanding progeroid 
syndromes in order to develop alternative treatments 
for these devastating pediatric diseases.  
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